Evaluación del riesgo de fenómenos trombóticos tras el uso de factor VII activado

Martínez López, M. C; Alcaraz Romero, A. J; Martínez López, A. B; Fernández-Llamazares, C. M; Ramos Navarro, C.
An. pediatr. (2003, Ed. impr.) ; 79(3): 177-181, sept. 2013. ilus, tab
Artículo en Español | IBECS (España) | ID: ibc-116570

Documentos relacionados

  1. [Risk assessment of thrombotic events after the use of activated factor VII].
  2. The Judicious Use of Recombinant Factor VIIa.
  3. Trends in the Use of Recombinant Activated Factor VII and Prothrombin Complex Concentrate in Heart Transplant Patients in Virginia.
  4. Systemic venous thrombosis after recombinant factor VIIa in the control of bleeding after cardiac surgery.
  5. Safety and efficacy of recombinant activated factor VII: a randomized placebo-controlled trial in the setting of bleeding after cardiac surgery.
  6. Recombinant activated factor VII for treatment of refractory hemorrhage after surgery for acute aortic dissection.
  7. Recombinant activated factor VIIa for the treatment of bleeding in major abdominal surgery including vascular and urological surgery: a review and meta-analysis of published data.
  8. The danger of using a sledgehammer to crack a nut: ROTEM-guided administration of recombinant activated factor VII in a patient with refractory bleeding post-ventricular assist device implantation.
  9. Use of recombinant activated factor VII for controlling refractory postoperative bleeding in children undergoing cardiac surgery with cardiopulmonary bypass.
  10. Experience with recombinant activated factor VII for severe post-partum hemorrhage in Japan, investigated by Perinatology Committee, Japan Society of Obstetrics and Gynecology.